The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

Living in disadvantaged neighborhoods influences stress-related genes, which may contribute to aggressive prostate cancer in African American men

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Those living in disadvantaged neighborhoods have significantly higher activity of stress-related genes, research suggests, which could contribute to higher rates of aggressive prostate cancer in African American men. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

People across Croatia gain access to advanced radiosurgery close to home at UPMC Hillman Cancer Center in Zabok

UPMC Hillman Cancer Center at Zabok General Hospital in Croatia is expanding access to the most advanced radiosurgery services for people across the country with the introduction of the Varian TrueBeam stereotactic body radiation therapy and stereotactic radiosurgery system. The new system delivers radiosurgery treatment with pinpoint accuracy and image-guided precision in a shorter amount of time than current conventional treatments.
In Brief

VCU Massey, MD Anderson researchers awarded $7.3M grant to launch breast cancer clinical trial

Venkata Lokesh BattulaClinton YamA multidisciplinary team of researchers at VCU Massey Comprehensive Cancer Center and MD Anderson Cancer Center has been awarded a $7.3 million grant from the U.S. Department of Defense to fund a novel clinical trial targeting one of the most aggressive and hard-to-treat forms of breast cancer: metastatic triple-negative breast cancer. 
Clinical Roundup

Decipher Prostate Test predicts chemo benefit in metastatic prostate cancer, phase III trial shows

The Decipher Prostate Genomic Classifier predicts which patients with metastatic cancer are likely to benefit from treatment intensification with the chemotherapy docetaxel and which are not likely to benefit and can therefore avoid unnecessary toxicity, according to findings by University College London and Veracyte, Inc., a genomic diagnostic company. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account